Endometriosis Medical Cannabis UK: Pain Management

Endometriosis and Medical Cannabis in the UK

• Endometriosis affects an estimated 1.5 million women and people with periods in the UK, causing chronic pelvic pain.
• Medical cannabis is prescribable for endometriosis-related pain in the UK when standard treatments have failed.
• The endocannabinoid system plays a direct role in reproductive pain, making cannabis a mechanistically relevant treatment.
• Both CBD and THC are used; CBD-dominant products are typically the first-line choice for endometriosis.

Endometriosis is chronically underdiagnosed in the UK, with patients waiting an average of seven to eight years for a definitive diagnosis. Once diagnosed, many patients cycle through hormonal treatments and NSAIDs without finding adequate pain relief, making medical cannabis an important option in the treatment toolkit.

Evidence for Cannabis in Endometriosis Pain

• A 2020 survey by EndoActive found 13% of Australian endometriosis patients used cannabis for symptom management, with high rates of reported efficacy.
• Endometriosis cells have been found to express CB1 and CB2 receptors, suggesting direct cannabinoid activity within lesions.
• UK endometriosis patient surveys consistently show high interest in cannabis-based pain management.
• Endometriosis UK has acknowledged cannabis as an area requiring more clinical research and better patient access.

The evidence base for cannabis in endometriosis is still emerging, but the biological rationale and patient-reported outcomes are encouraging. UK specialist clinics are increasingly seeing endometriosis patients and developing tailored prescribing protocols for pelvic pain.

How UK Endometriosis Patients Access Medical Cannabis

• A confirmed endometriosis diagnosis (via laparoscopy or imaging) and treatment failure documentation are required.
• Self-referral to a UK private cannabis clinic; no gynaecologist referral is required at most providers.
• Attend a virtual or in-person consultation; the prescriber will assess pelvic pain severity and current management.
• Products are typically dosed cyclically, with higher doses during menstrual flares, adjusted at follow-up.

UK endometriosis patients report particular benefit from evening dosing ahead of anticipated pain flares and during menstruation. Specialist prescribers experienced in gynaecological pain are best placed to manage this indication, and patients are encouraged to seek out clinicians with relevant background.

Costs for Endometriosis Patients in the UK

• Initial specialist consultation: £150–£280 at UK private cannabis clinics.
• Monthly CBD-dominant oil prescription: approximately £70–£130.
• Monthly balanced THC:CBD products (for more severe pain): approximately £120–£220.
• NHS endometriosis cannabis prescriptions are not currently available; private prescribing is the only realistic route.

The monthly cost of medical cannabis for endometriosis is often less than the cumulative cost of over-the-counter painkillers, heat therapy, and other self-management tools that patients use to manage symptoms. Patients who work closely with their prescriber to optimise their protocol typically achieve the best long-term outcomes.